AC Immune Management
Management criteria checks 2/4
AC Immune's CEO is Andrea Pfeifer, appointed in Apr 2003, has a tenure of 21.67 years. total yearly compensation is CHF2.65M, comprised of 21.8% salary and 78.2% bonuses, including company stock and options. directly owns 2.45% of the company’s shares, worth €6.28M. The average tenure of the management team and the board of directors is 5.8 years and 6.7 years respectively.
Key information
Andrea Pfeifer
Chief executive officer
CHF 2.7m
Total compensation
CEO salary percentage | 21.8% |
CEO tenure | 21.7yrs |
CEO ownership | 2.4% |
Management average tenure | 5.8yrs |
Board average tenure | 6.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -CHF 40m |
Jun 30 2024 | n/a | n/a | -CHF 61m |
Mar 31 2024 | n/a | n/a | -CHF 55m |
Dec 31 2023 | CHF 3m | CHF 578k | -CHF 54m |
Sep 30 2023 | n/a | n/a | -CHF 68m |
Jun 30 2023 | n/a | n/a | -CHF 67m |
Mar 31 2023 | n/a | n/a | -CHF 69m |
Dec 31 2022 | CHF 2m | CHF 558k | -CHF 71m |
Sep 30 2022 | n/a | n/a | -CHF 73m |
Jun 30 2022 | n/a | n/a | -CHF 76m |
Mar 31 2022 | n/a | n/a | -CHF 75m |
Dec 31 2021 | CHF 2m | CHF 530k | -CHF 73m |
Sep 30 2021 | n/a | n/a | -CHF 71m |
Jun 30 2021 | n/a | n/a | -CHF 74m |
Mar 31 2021 | n/a | n/a | -CHF 71m |
Dec 31 2020 | CHF 2m | CHF 520k | -CHF 62m |
Sep 30 2020 | n/a | n/a | -CHF 62m |
Jun 30 2020 | n/a | n/a | -CHF 25m |
Mar 31 2020 | n/a | n/a | -CHF 26m |
Dec 31 2019 | CHF 2m | CHF 510k | CHF 45m |
Sep 30 2019 | n/a | n/a | CHF 50m |
Jun 30 2019 | n/a | n/a | CHF 18m |
Mar 31 2019 | n/a | n/a | CHF 24m |
Dec 31 2018 | CHF 2m | CHF 455k | -CHF 51m |
Sep 30 2018 | n/a | n/a | -CHF 32m |
Jun 30 2018 | n/a | n/a | -CHF 27m |
Mar 31 2018 | n/a | n/a | -CHF 29m |
Dec 31 2017 | CHF 2m | CHF 404k | -CHF 26m |
Compensation vs Market: Andrea's total compensation ($USD2.95M) is above average for companies of similar size in the German market ($USD900.29K).
Compensation vs Earnings: Andrea's compensation has increased whilst the company is unprofitable.
CEO
Andrea Pfeifer (67 yo)
21.7yrs
Tenure
CHF 2,650,000
Compensation
Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 21.7yrs | CHF 2.65m | 2.45% € 6.3m | |
CFO & VP of Finance | 2.7yrs | no data | 0.013% € 32.7k | |
Chief Technical Operations Officer | 5.8yrs | no data | 0.025% € 63.6k | |
Chief Administrative Officer | 9.4yrs | no data | 0.32% € 809.7k | |
Chief HR Officer | 2.7yrs | no data | 0.020% € 52.3k | |
Chief Scientific Officer | less than a year | no data | 0.0032% € 8.2k | |
Senior VP of Investor Relations & Corporate Communications | no data | no data | no data | |
General Counsel | no data | no data | no data | |
VP of U.S. Finance & Corporate Development | 2.7yrs | no data | no data | |
Head of AD - SME | 14.9yrs | no data | no data | |
Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer | 8.8yrs | no data | no data | |
VP & Head of Clinical Development | no data | no data | no data |
5.8yrs
Average Tenure
54.5yo
Average Age
Experienced Management: IMR's management team is seasoned and experienced (5.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 8.6yrs | CHF 2.65m | 2.45% € 6.3m | |
Chairman of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Non-Executive Chairman | 6.7yrs | CHF 179.00k | 0.039% € 101.1k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | CHF 5.00k | no data | |
Member of Scientific Advisory Board | no data | CHF 105.00k | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Vice Chair | 3.2yrs | CHF 163.00k | 0.0092% € 23.8k | |
Head of Clinical Advisory Board | no data | no data | no data |
6.7yrs
Average Tenure
74.5yo
Average Age
Experienced Board: IMR's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 09:09 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AC Immune SA is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Thomas Shrader | BTIG |
Alethia Young | Credit Suisse |
Andrew Fein | H.C. Wainwright & Co. |